On May 26, 2020, Royal Philips announced it had received 510(k) clearance from the FDA for its wearable biosensor (Philips Biosensor BX100) to help manage confirmed and suspected COVID-19 patients in the hospital. The next generation wireless wearable biosensor enhances clinical surveillance in the Philips patient deterioration detection solution to help clinicians detect risk so they can intervene earlier and help improve care for patients in lower acuity care areas.

The solution had already received CE mark, and was currently in use with the first install at the OLVG Hospital in the Netherlands to help manage the triage and clinical surveillance of COVID-19 patients.